
SynBioBeta Speaker
Michael Chen
Nuclera
CEO & Mng. Director
Michael Chen is the co-founder and CEO of Nuclera, a Cambridge UK and Boston US based life science tools company revolutionizing protein accessibility through the eProtein Discovery rapid protein access benchtop platform. With a mission to improve human health, Michael and his classmates founded Nuclera in response to the costly barriers to protein access for research and drug discovery. As CEO, he drives core inventions, sets the company's vision and strategy, and oversees its growth across two continents with over 100 employees.Before Nuclera, Michael was an award-winning structural biologist. His work resulted in numerous high impact publications including Nature. Michael holds a BSc in Chemistry from the Georgia Institute of Technology and a PhD in Structural Biology/Chemistry from the University of Cambridge and the National Institutes of Health.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Michael
This Year
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon













































































































































































































































































